Blood thinner dosing gets a precision makeover
NCT ID NCT07654634
First seen Jun 23, 2026 · Last updated Jun 23, 2026
Summary
This observational study tracks 5,000 people taking common blood thinners (like rivaroxaban or apixaban) or antiplatelet drugs (like aspirin) for conditions such as atrial fibrillation, blood clots, or heart attack. Researchers regularly measure drug levels in the blood to see how they relate to side effects like bleeding or clotting events. The goal is to find the best dosing ranges and build a model to predict the right dose for each person.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ISCHEMIC STROKE are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Xiangya Third Hospital of Central South University
Changsha, Hunan, 410000, China
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
What this could lead to
If successful, this could lead to more precise dosing of blood thinners, reducing the risk of clots or bleeding for patients with heart conditions or stroke.
What could go wrong
This is an observational study, not a treatment trial, so it won't directly test a new drug or cure. Results may not apply to all patients or lead to immediate changes in care.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.